Could an endoscopic procedure help you keep weight off after stopping GLP-1 medications?

Key Takeaways:

• Some people who stop GLP-1 use regain most, if not all, of the weight they lost from being on the medication.
• The REVEAL-1 study explores whether duodenal mucosal resurfacing, a minimally invasive endoscopic procedure, could help patients maintain their weight loss after they stop taking GLP-1s.
• The early findings of the study are encouraging.

By now, most people are somewhat familiar with GLP-1 medications, a class of drugs that is helping millions of overweight and obese patients find weight loss success. 

For many people taking drugs like tirzepatide or semaglutide, losing weight isn’t the hardest part. Keeping it off, however, can be extremely difficult.

In fact, we are seeing people regain most, if not all, of the weight they lost after stopping GLP-1 use. 

Here at the WVU Medicine Advanced Center for Endoscopy, we are now seeing patients maintaining their weight loss one year after discontinuing GLP-1 medications. 

How are these patients achieving lasting success?

WVU Medicine J.W. Ruby Memorial Hospital is a research hub in REVEAL-1, a study exploring whether a minimally invasive endoscopic procedure could help patients maintain their weight loss after they stop taking GLP-1s.

Anyone who has followed the conversation around GLP-1 medications knows the challenge: what happens when treatment stops? 

The drugs, originally developed to help manage diabetes, are expensive and not covered by many insurance plans. Affordability aside, many patients experience unpleasant side effects. 

Data shows us that these factors lead most GLP-1 users to stop taking the medications less than one year after starting them.

The REVEAL-1 study has focused on people who already achieved significant weight loss using GLP-1 medications and wanted – or needed – to stop taking them.

The study followed 22 patients taking GLP-1 medications for an average of 1.4 years. Before stopping treatment, they already achieved an average weight loss of about 24 percent.

Rather than simply discontinuing medication and hoping for the best, participants underwent a procedure called duodenal mucosal resurfacing (DMR), performed using an investigational device called Revita.

The procedure targets the duodenum, the first section of the small intestine. While many people think of the digestive tract as a passage that simply moves food through the body and breaks it down, we now understand that the duodenum plays a much more sophisticated role.

A key regulator and a sensor for nutrients, the duodenum contains specialized cells involved in hormone signaling and communication between the gut, pancreas, and brain.

Scientists believe years of diets that are high in fat and refined carbohydrates can change the surface of the duodenum and alter the ways these signaling pathways function.

The question driving this research is a compelling one: could restoring healthy tissue in the duodenum get these signaling pathways working normally once again?

In simple terms, the DMR procedure uses controlled heat to resurface the lining of the duodenum. The new lining that grows back is thought to be healthier and better able to regulate these nutrient signals.

While we continue to study exactly how this process works, the early findings are encouraging.

Six months after stopping GLP-1 therapy, study participants experienced only minor weight regain, an average of just 1.5 percent.

One year out, they had kept off most of their weight loss, regaining only a small fraction of what they had lost — far less than the substantial rebound typically seen after these medications are stopped.

For patients who fear a dramatic bounce-back the moment they come off treatment, that distinction matters.

As for the procedure itself, it is a minimally invasive, outpatient endoscopy, and the technology continues to evolve to make it faster and more efficient.

Just as important, we have seen no major complications in patients following DMR.

Our research is still ongoing, and WVU Medicine is helping lead the way. Revita is investigational and available only through clinical trials; it is not yet approved for use outside of research.

Still, for patients who have struggled with the reality that obesity often requires lifelong treatment, studies like REVEAL-1 offer something increasingly valuable: another option.

We are hopeful that for the millions of people wondering what comes after GLP-1 medications, the future may look very different from what it did just a few years ago.